Sallee F R, Pollock B G, Stiller R L, Stull S, Everett G, Perel J M
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pennsylvania 15213.
J Clin Pharmacol. 1987 Oct;27(10):776-81. doi: 10.1002/j.1552-4604.1987.tb02995.x.
Pimozide is a neuroleptic drug with dopamine receptor and calcium channel blocking activity that is used in the treatment of Tourette's syndrome. A comparison of the pharmacokinetics of pimozide was made in children and adults with Tourette's syndrome. Seven adults (ages 23-39) and four children (ages 6-13) received a single 2-mg oral dose of pimozide and a minimum of nine blood samples were collected over a four-day period. Mean elimination half-life of pimozide in children was 66 hours compared with 111 hours in adults with Tourette's syndrome. Significant interindividual variability of pimozide pharmacokinetics was found in both adults and children with Tourette's syndrome. The pharmacokinetics of pimozide in patients with Tourette's syndrome differs from that reported in adult populations with chronic schizophrenia.
匹莫齐特是一种具有多巴胺受体和钙通道阻滞活性的抗精神病药物,用于治疗抽动秽语综合征。对患有抽动秽语综合征的儿童和成人的匹莫齐特药代动力学进行了比较。7名成年人(年龄23 - 39岁)和4名儿童(年龄6 - 13岁)口服了2毫克的匹莫齐特单次剂量,并在四天内至少采集了9份血样。患有抽动秽语综合征的儿童中匹莫齐特的平均消除半衰期为66小时,而患有抽动秽语综合征的成年人中为111小时。在患有抽动秽语综合征的成年人和儿童中均发现匹莫齐特药代动力学存在显著的个体间差异。患有抽动秽语综合征患者的匹莫齐特药代动力学与成年慢性精神分裂症患者中报道的不同。